"Similar to the nation’s most renowned community cancer practices, Mission Cancer + Blood offers on-site labs and chemotherapy infusion suites, financial counseling, clinical trials, multi-disciplinary tumor boards and quality of care that matches and even surpasses the most recognized institutions. Every patient will be assigned a care team that includes a Physician, Nurse, and possibly an Advanced Practice Provider, to supervise the care and advocate for the patient. Our team is eager to get to know you and how they can help. We develop a personalized plan that is unique to each diagnosis. No more traveling outside the state for top-tier medical care. With locations all across Iowa, we are right in your back yard and by your side."

During the past decade, Medical Oncology and Hematology Associates-Des Moines conducted 171 clinical trials. In the 10-year time frame, 171 clinical trials started and 137 clinical trials were completed, i.e. on average, 80.1% percent of trials that started reached the finish line to date. In the past 5 years, 60 clinical trials started and 63 clinical trials were completed. i.e. 105% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medical Oncology and Hematology Associates-Des Moines" #1 sponsor was "National Cancer Institute (NCI)" with 164 trials, followed by "Alliance for Clinical Trials in Oncology" with 45 trials sponsored, "SWOG Cancer Research Network" with 45 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 23 trials sponsored and "Gynecologic Oncology Group" with 23 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medical Oncology and Hematology Associates-Des Moines" #1 collaborator was "National Cancer Institute (NCI)" with 160 trials as a collaborator, "NRG Oncology" with 37 trials as a collaborator, "Canadian Cancer Trials Group" with 9 trials as a collaborator, "NCIC Clinical Trials Group" with 8 trials as a collaborator and "Cancer and Leukemia Group B" with 7 trials as a collaborator. Other collaborators include 61 different institutions and companies that were collaborators in the rest 48 trials.

According to Clinical.Site data, the most researched conditions in "Medical Oncology and Hematology Associates-Des Moines" are "Recurrent Ovarian Carcinoma" (19 trials), "Recurrent Fallopian Tube Carcinoma" (15 trials), "Recurrent Primary Peritoneal Carcinoma" (14 trials), "Recurrent Breast Carcinoma" (12 trials) and "Fallopian Tube Transitional Cell Carcinoma" (11 trials). Many other conditions were trialed in "Medical Oncology and Hematology Associates-Des Moines" in a lesser frequency.

Most popular intervention types in "Medical Oncology and Hematology Associates-Des Moines" are "Drug" (261 trials), "Other" (215 trials), "Biological" (121 trials), "Procedure" (77 trials) and "Radiation" (45 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (109 trials), "Quality-of-Life Assessment" (82 trials), "Questionnaire Administration" (58 trials), "Paclitaxel" (46 trials) and "Carboplatin" (39 trials). Other intervention names were less common.

The vast majority of trials in "Medical Oncology and Hematology Associates-Des Moines" are 239 trials for "All" genders, 75 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are NaN active trials in "Medical Oncology and Hematology Associates-Des Moines". undefined are not yet recruiting, 84 are recruiting, 129 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 85 completed trials in Medical Oncology and Hematology Associates-Des Moines, 5 suspended trials, and 21 terminated clinical trials to date.

Out of the total trials that were conducted in Medical Oncology and Hematology Associates-Des Moines, 12 "Phase 1" clinical trials were conducted, 156 "Phase 2" clinical trials and 157 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 11 trials that are defined as “Not Applicable".